1215343-94-4
1215343-94-4
Chemical Structure
(Rac)-Talinolol-d5
- CAS No.: 1215343-94-4
- Formula:C20H28D5N3O3
- Molecular Weight:368.53
IUPAC Name: 1-(4-(3-(tert-butylamino)-2-hydroxypropoxy-1,1,2,3,3-d5)phenyl)-3-cyclohexylurea
InChIKey: MXFWWQICDIZSOA-BZLWXWEZSA-N
SMILES: O(C(C(C(NC(C)(C)C)([2H])[2H])(O)[2H])([2H])[2H])C1=CC=C(NC(NC2CCCCC2)=O)C=C1
Biological Activity: (Rac)-Talinolol-d5 is the racemate of Talinolol. Talinolol (Cordanum) is a long-acting, cardioselective β1-adrenergic receptor blocker. Talinolol exhibits cardioprotective and antihypertensive activities. Talinolol is also a well-known and frequently used probe substrate for P-glycoprotein (P-gp) activity[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
(Rac)-Talinolol-d5 | (Rac)-Talinolol-d5 is the racemate of Talinolol. Talinolol (Cordanum) is a long-acting, cardioselective β1-adrenergic receptor blocker. Talinolol exhibits cardioprotective and antihypertensive activities. Talinolol is also a well-known and frequently used probe substrate for P-glycoprotein (P-gp) activity. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Talinolol (Standard) | ≥98% | Talinolol (Standard) is the analytical standard of Talinolol (HY-108286). This product is intended for research and analytical applications. Talinolol (Cordanum) is a long-acting, cardioselective β1-adrenergic receptor blocker. Talinolol exhibits cardioprotective and antihypertensive activities. Talinolol is also a well-known and frequently used probe substrate for P-glycoprotein (P-gp) activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Talinolol | 99.56% | Talinolol (Cordanum) is a long-acting, cardioselective β1-adrenergic receptor blocker. Talinolol exhibits cardioprotective and antihypertensive activities. Talinolol is also a well-known and frequently used probe substrate for P-glycoprotein (P-gp) activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Assmann I. The actions of talinolol, a beta 1-selective beta blocker, in cardiac arrhythmia and acute myocardial infarction. Curr Med Res Opin. 1995;13(6):325-42. [Content Brief]
- [3]. Kara ZP, et, al. The effects of P-glycoprotein inhibitor zosuquidar on the sex and time-dependent pharmacokinetics of parenterally administered talinolol in mice. Eur J Pharm Sci. 2021 Jan 1;156:105589. [Content Brief]
